Detection of minimal residual disease in patients with cancer: A review of techniques, clinical implications, and emerging therapeutic consequences

Cancer Detection and Prevention

Volumn 24, Issue 4, 2000, Pages 376-403

  Kostler, W J ^a   Brodowicz, T ^a   Hejna, M ^a   Wiltschke, C ^a   Zielinski, C C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer; Detection; Disease; Minimal; Residual

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ARTICLE; BONE MARROW PURGING; DRUG SCREENING; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PROGNOSIS; TUMOR EMBOLISM;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BONE MARROW PURGING; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM CIRCULATING CELLS; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PROGNOSIS; TUMOR STEM CELL ASSAY;

EID: 0033789835     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (214)

1. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate
2. Methods for detection of micrometastatic carcinoma cells in bone marrow, blood and lymphnodes
3. Disseminated tumor cells: Diagnosis, prognostic relevance, phenotyping and therapeutic strategies
4. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients
5. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
6. Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-up
7. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: Methodological aspects of detection and prognostic significance
8. Detection of tumor cells in bone marrow of patiens with primary breast cancer: A prognostic factor for distant metastasis
9. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients
10. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases
11. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma
12. Prognostic significance of bone marrow micrometastases in patients with gastric cancer
13. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer
14. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse
15. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumours
16. Immunocytochemical monitoring of micrometastatic disease: Reduction of prostate cancer cells in bone marrow by androgen deprivation
17. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up
18. The fate of bone marrow micrometastases in patients with primary breast cancer
19. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
20. Meta-analyses of studies on bone marrow micrometastases: An independent prognostic impact remains to be substantiated
21. What's new in TNM?
22. Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease
23. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes)
24. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone morrow
25. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastasis
26. First international ISHAGE symposium on minimal residual cancer
27. Immunocytochemical detection of isolated epithelial cells in bone marrow: Non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase
28. Correlation of specific keratins with different types of epithelial differentiation: Monoclonal antibody studies
29. Illegitimate transcription: Transcription of any gene in any cell type
30. Micrometastatic cancer cells in bone marrow: In vitro detection with anticytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies
31. Results of iliac crest biopsies taken from 1465 patients with primary breast cancer
32. Immunofluorescent monoclonal antibody detection of breast cancer in bone marrow: Sensitivity in a model system
33. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma
34. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood
35. Immunobead-PCR: A technique for the detection of circulating rumor cells using immunomagnetic beads and the polymerase chain reaction
36. Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation
37. Detection of minimal malignant cell infiltration in the bone marrow of patients with solid tumours, non-Hodgkin lymphomas and leukaemias
38. Epithelial tumor cells in bone marrow of patients with colorectal cancer: Immunocytochemical detection, phenotypic characterization, and prognostic significance
39. Keratin-positive reticulum cells in fine needle aspirates and touch imprints of hyperplastic lymph nodes. A possible pitfall in the immunocytochemical diagnosis of metastatic carcinoma
40. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer
41. Ber-EP4: New monoclonal antibody which distinguishes epithelial from mesothelial
42. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR
43. Detection of disseminated tumor cells in peripheral blood of colorectal cancer patients
44. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
45. Tumor cells in blood shed from the surgical field
46. In vivo monitoring of the death rate of artificial murine pulmonary micrometastases
47. Occult epithelial tumor cells detected in bone marrow by an enzyme immunoassay specific for cytokeratin 19
48. Detection of immunocytochemically stained rare events using image analysis
49. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction
50. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma
51. Identification of p53 gene mutations in bladder cancers and urine samples
52. Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA)
53. Detection of minimal residual cells carrying the t(14; 18) by DNA sequence amplification
54. Use of oligonucleotide probes directed against T cell antigen receptor gamma delta variable-(diversity)-joining junctional sequences as a general method for detecting minimal residual disease in acute lymphoblastic leukemias
55. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction
56. Genetic diagnosis of lymph-node metastasis in colorectal cancer
57. Molecular detection of primary bladder cancer by microsatellite analysis
58. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination
59. Limitation of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow
60. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells
61. Diagnosis of micrometastases by the amplification of tissue-specific genes
62. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation
63. Cut out or poke in - The key to the world of single genes: Laser micromanipulation as a valuable tool on the look-out for the origin of disease
64. Modeling and analysis of competitive RT-PCR
65. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay
66. Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma
67. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using functional region specific TaqMan probes
68. Establishment of micrometastatic carcinoma cell lines: A novel source of tumor cell vaccines
69. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission
70. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques
71. Levels of detection of tumor cells in human bone marrow with or without prior culture
72. Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: A review
73. The detection of minimal lymphoma by molecular and combined culture-methods
74. Minimal residual disease in autologous hematopoietic harvests from breast cancer patients
75. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40
76. Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization
77. Detection of gene deletion in single metastatic tumour cells in lymph node tissue by fluorescent in-situ hybridisation
78. Improved sensitivity of BCR-ABL detection: A triple-probe three-color fluorescence in situ hybridization system
79. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia
80. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7)
81. Immunocytological detection of micrometastatic cells: Comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients
82. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction
83. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival
84. The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma
85. Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins
86. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
87. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer
88. Detection of micrometastases in patients with primary breast cancer
89. Micrometastases in breast cancer: Long-term follow-up of the first patient cohort
90. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction
91. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group
92. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Reevaluation with longer follow-up
93. Detection of tumor cells in bone marrow: A deciding aid for adjuvant therapy in node negative patients with breast cancer. Concept for a multicenter study and results of the pilot phase
94. Clinical significance of bone marrow metastasis as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation
95. Detection of small cell lung cancer bone marrow metastasis by tumor stem cell assay
96. Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody
97. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer
98. Detection of disseminated lung cancer cells in lymph nodes: Impact on staging and prognosis
99. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma
100. Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer
101. Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer
102. Detection of tumor cells in bone marrow of patients with prostatic carcinoma by immunocytochemical techniques
103. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction
104. Detection of hematogenous micrometastasis in patients with prostate cancer
105. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy
106. Molecular starring of prostate cancer: II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate Specific membrane antigen
107. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen
108. Detection of circulating tumor cells in men with localized prostate cancer
109. Positive prostate-specific antigen circulating cells detected by reverse transcriptase - Polymerase chain reaction does not imply the presence of prostatic micrometastases
110. Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: Implications for the detection of hematogenous prostate cells and standardization
111. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate Cancer
112. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy
113. Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: CorrelatiOn to preoperative serum prostate-specific antigen
114. Circulating micrometastases following oncological surgery
115. Detection of submicroscopic lymph node metastasis with polymerase chain reaction in patients with malignant melanoma
116. Occult tumour cells in the lymph nodes of patients with pathological state I malignant melanoma. An immunohistological study
117. New prognostic factors in melanoma: mRNA tumour markers
118. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer
119. Immunocytochemical detection of breast cancer cells: A comparison of three attachment factors
120. Successful xenotransplantation of human lung cancer correlates with the metastatic phenotype
121. Biological diversity in metastatic neoplasms: Origins and implications
122. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells
123. Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: Association with early lymphatic spread of tumour cells
124. Loss of HLA class I antigen expression on disseminated tumor cells in bone marrow of breast cancer patients relates to poor prognosis
125. Differential expression of proliferation-associated molecules in individual micro-metastatic carcinoma cells
126. Characterization of magnetobead separated disseminated tumour cells from bone marrow: A path to individual tumor therapy?
127. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
128. p53 gene mutations are not required for early dissemination of cancer cells
129. p53 expression and aneuploidies of chromosome 17 in epithelial cells in bone marrow of cancer patients
130. Genetic control of cancer metastases
131. Tumor-antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease
132. Prognostic relevance of cathepsin D detection in micrometastatic cells in the bone marrow of patients with primary breast cancer
133. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer
134. Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer
135. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
136. Allelic loss of chromosome 18q and prognosis in colorectal cancer
137. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
138. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients
139. Tumor cell contamination of bone marrow harvest products: Clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy
140. Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor
141. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
142. Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia
143. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest
144. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
145. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer
146. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy
147. Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts
148. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo
149. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
150. Autologous bone marrow transplantation in breast cancer: Separation of clonogenic tumor cell colonies by gradient fractionation
151. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer. Effect of ex vivo purging with 4-hydroperoxycyclophosphamide
152. Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow
153. Bone marrow purging procedure in Burkitt's lymphoma with monoclonal antibodies and complement: Quantification by a liquid cell culture monitoring system
154. Proliferation and survival of mammary carcinoma cells are influenced by culture conditions used for ex vivo expansion of CD34(+) blood progenitor cells
155. Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins
156. Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma
157. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase - Polymerase chain reaction
158. Transplantation of enriched CD34- positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment
159. Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission
160. Monitoring minimal residual disease
161. Adenovirus-mediated gene transfer to human breast tumor cells: An approach for cancer gene therapy and bone marrow purging
162. BCR-ABL anti-sense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase
163. Decreased expression of ICAM-1 and its introduction by tumour necrosis factor on breast-cancer cells in vitro
164. Cancer vaccines
165. Apoptosis in antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody 17-1A against human colorectal carcinoma cells: Enhancement with interferon gamma
166. Immunotoxins: Magic bullets or misguided missiles?
167. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors
168. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial
169. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
170. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A
171. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
172. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
173. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer
174. Bispecific antibody targeted T cell therapy of ovarian cancer: Clinical results and future directions
175. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - Long-lasting, complete remissions can be induced
176. Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: Significance of nodal micrometastasis
177. A classification of transplantable tumors in Nb rats controlled by estrogen from dormancy to autonomy
178. Chromosome 17-mediated dormancy of AT6. 1 prostate cancer micrometastases
179. How tumors become angiogenic
180. The effect of immunosuppression on pre-existing cancers
181. Cancer dormancy: Opportunities for new therapeutic approaches
182. Stromal cell effects on clonal growth of tumors
183. Increased hematopoietic progenitor cell maintenance in long-term bone marrow cultures containing minimal numbers of contaminating breast cancer cells
184. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
185. Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease
186. The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis
187. Micrometastases in bone marrow in patients with primary breast cancer: Evaluation as an early predictor of bone metastasis
188. Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods
189. Detection of small cell lung cancer bone marrow metastases by immunofluorescence
190. Ewing family tumors: Potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples
191. Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer
192. Detection of bladder cancer recurrence by microsatellite analysis of urine
193. Detection of tumor cells in peripheral blood samples from patients with germ cell tumors using immunocytochemical and reverse transcriptase - Polymerase chain reaction techniques
194. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction
195. Immunological detection and definition of minimal residual neuroblastoma disease in bone marrow samples obtained during or after therapy
196. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma
197. Disseminated epithelial tumor cells in bone marrow of patients with esophageal cancer: Detection and prognostic significance
198. Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by immunocytochemical staining
199. Immunocytochemical detection and prognostic significance of epithelial tumor cells in bone marrow of patients with pancreatic carcinoma
200. Immunocytologic detection of isolated tumor cells in bone marrow of patients with squamous cell carcinomas of the head and neck region
201. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck
202. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: A clinical two-center study
203. RT-PCR for tyrosinase-mRNA- positive cells in peripheral blood: Evaluation strategy and correlation with known prognostic markers in 123 melanoma patients
204. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay
205. A polymerase chain reaction - Based semiquantitative assessment of malignant melanoma Cells in peripheral blood
206. Identification of bone marrow micrometastases in patients with prostate cancer
207. Enhanced reverse transcriptase - Polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer
208. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays
209. The prognostic significance of tumor cell detection in bone marrow of patients with breast cancer
210. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
211. Detection of occult tumour cells in bone marrow and blood in breast cancer patients - Methods and clinical significance
212. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: A new prognostic factor
213. Micrometastases in bone marrow of patients with cancers in the head and neck area
214. Staging of head and neck cancer